Foundayo Reduces Sleep Apnea Breathing Interruptions by 44%

Eli Lilly said on ​Monday its oral weight-loss ‌drug Foundayo significantly reduced breathing interruptions during ​sleep in obese ​adults with moderate-to-severe obstructive sleep ⁠apnea, meeting the ​main goal of a ​late-stage study. Foundayo reduced breathing interruptions by up to 44% ​on average at ​52 weeks as measured by ‌a ⁠diagnostic scale used to measure the severity of sleep apnea, ​Lilly said. Obstructive ​sleep ⁠apnea is a sleep disorder ​in which the ​upper ⁠airway repeatedly collapses during sleep, lowering oxygen ⁠levels ​and disrupting breathing.